enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has received a consensus recommendation of “Buy” from the eleven research firms that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $29.78.

A number of equities research analysts have issued reports on ENGN shares. Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James started coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of enGene in a report on Monday, December 23rd.

enGene Stock Performance

Shares of NASDAQ ENGN opened at $6.70 on Friday. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The stock has a market capitalization of $296.27 million, a price-to-earnings ratio of -11.55 and a beta of -0.65. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock’s fifty day simple moving average is $7.32 and its 200 day simple moving average is $7.47.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. As a group, sell-side analysts forecast that enGene will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enGene

Large investors have recently bought and sold shares of the business. Wolverine Asset Management LLC acquired a new position in enGene during the 3rd quarter worth about $37,000. Point72 Asset Management L.P. grew its stake in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in enGene during the 4th quarter worth $69,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.